Vor Biopharma (NASDAQ:VOR) Stock Price Down 5% – Here’s Why

Vor Biopharma Inc. (NASDAQ:VOR)’s stock price fell 5% during trading on Monday . The stock traded as low as $17.26 and last traded at $17.18. 143,547 shares traded hands during trading, a decline of 87% from the average daily volume of 1,096,618 shares. The stock had previously closed at $18.09.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on the stock. HC Wainwright restated a “buy” rating and issued a $31.00 price objective on shares of Vor Biopharma in a research note on Monday, May 18th. Wedbush lifted their target price on Vor Biopharma from $15.00 to $18.00 and gave the stock a “neutral” rating in a research report on Thursday, May 14th. Wall Street Zen downgraded Vor Biopharma from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. Jefferies Financial Group raised Vor Biopharma to a “strong-buy” rating in a research report on Thursday, April 30th. Finally, Weiss Ratings upgraded Vor Biopharma from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, June 30th. Two equities research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $42.25.

Vor Biopharma Stock Performance

The company has a 50-day simple moving average of $16.02 and a 200-day simple moving average of $15.10.

Vor Biopharma (NASDAQ:VOR) last posted its quarterly earnings results on Monday, March 30th. The company reported $307.61 EPS for the quarter. Sell-side analysts forecast that Vor Biopharma Inc. will post -2.51 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Vor Biopharma

A number of large investors have recently made changes to their positions in the stock. RA Capital Management L.P. boosted its holdings in Vor Biopharma by 172.7% during the fourth quarter. RA Capital Management L.P. now owns 5,404,998 shares of the company’s stock worth $70,697,000 after buying an additional 3,422,697 shares in the last quarter. Fcpm Iii Services B.V. lifted its position in shares of Vor Biopharma by 852.8% during the 4th quarter. Fcpm Iii Services B.V. now owns 3,617,354 shares of the company’s stock valued at $47,315,000 after acquiring an additional 3,237,714 shares during the period. Frazier Life Sciences Management L.P. acquired a new stake in shares of Vor Biopharma during the 4th quarter valued at approximately $33,275,000. Paradigm Biocapital Advisors LP purchased a new stake in shares of Vor Biopharma during the 4th quarter worth approximately $22,890,000. Finally, NEXTBio Capital Management LP purchased a new stake in shares of Vor Biopharma during the 4th quarter worth approximately $13,080,000. Hedge funds and other institutional investors own 97.29% of the company’s stock.

Vor Biopharma Company Profile

Vor Biopharma, Inc is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company’s proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient’s immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability.

The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).